📊 SRZNW Key Takeaways
Is Surrozen, Inc./DE (SRZNW) a Good Investment?
Surrozen exhibits severe balance sheet deterioration with negative stockholders' equity of -$187.8M, indicating technical insolvency. The company burns ~$30M annually with only $3.5M in revenue and no growth trajectory, creating an unsustainable cash situation despite adequate near-term liquidity. Fundamental viability depends entirely on external capital raises or transformative clinical outcomes, both representing high-risk catalysts.
Surrozen, Inc./DE Key Strengths (SRZNW)
- Cash position of $89.2M provides 2-3 years of runway at current burn rate
- Strong liquidity ratios (9.22x current/quick) ensure near-term operational continuity
- Active insider participation (11 Form 4 filings) suggests management engagement with company direction
SRZNW Stock Risks: Surrozen, Inc./DE Investment Risks
- Negative stockholders' equity of -$187.8M indicates technical insolvency and balance sheet impairment
- Operating cash burn of -$30.2M annually is unsustainable without external financing or revenue acceleration
- Minimal revenue of $3.5M with 0% YoY growth provides no evidence of commercial viability or path to profitability
- Liabilities of $286.5M exceed assets by $187.8M, creating significant capital structure risk and dilution potential
- Negative margins across all profitability metrics (-6960.8% net margin, -1210.6% operating margin)
Key Metrics to Watch
- Stockholders' equity trend - movement toward positive equity is critical for solvency
- Cash burn rate and cash runway - any material change impacts survival timeline
- Revenue growth acceleration - evidence of commercial traction or partnership deals
- Operating cash flow trajectory - path to sustainable cash generation
Surrozen, Inc./DE (SRZNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.22x current ratio provides a solid financial cushion.
SRZNW Profit Margin, ROE & Profitability Analysis
SRZNW vs Healthcare Sector: How Surrozen, Inc./DE Compares
How Surrozen, Inc./DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Surrozen, Inc./DE Stock Overvalued? SRZNW Valuation Analysis 2026
Based on fundamental analysis, Surrozen, Inc./DE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Surrozen, Inc./DE Balance Sheet: SRZNW Debt, Cash & Liquidity
SRZNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Surrozen, Inc./DE's revenue has declined by 15% over the 5-year period, indicating business contraction. The most recent EPS of $-21.67 indicates the company is currently unprofitable.
SRZNW Revenue Growth, EPS Growth & YoY Performance
SRZNW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $983.0K | -$27.0M | $-7.43 |
| Q3 2025 | $983.0K | -$1.4M | $-0.44 |
| Q2 2025 | N/A | $12.8M | $0.85 |
| Q1 2025 | N/A | -$8.8M | $-4.24 |
| Q3 2024 | N/A | -$1.4M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Surrozen, Inc./DE Dividends, Buybacks & Capital Allocation
SRZNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Surrozen, Inc./DE (CIK: 0001824893)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRZNW
What is the AI rating for SRZNW?
Surrozen, Inc./DE (SRZNW) has an AI grade of D with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRZNW's key strengths?
Claude: Cash position of $89.2M provides 2-3 years of runway at current burn rate. Strong liquidity ratios (9.22x current/quick) ensure near-term operational continuity.
What are the risks of investing in SRZNW?
Claude: Negative stockholders' equity of -$187.8M indicates technical insolvency and balance sheet impairment. Operating cash burn of -$30.2M annually is unsustainable without external financing or revenue acceleration.
What is SRZNW's revenue and growth?
Surrozen, Inc./DE reported revenue of $3.5M.
Does SRZNW pay dividends?
Surrozen, Inc./DE does not currently pay dividends.
Where can I find SRZNW SEC filings?
Official SEC filings for Surrozen, Inc./DE (CIK: 0001824893) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRZNW's EPS?
Surrozen, Inc./DE has a diluted EPS of $-32.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SRZNW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Surrozen, Inc./DE has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SRZNW stock overvalued or undervalued?
Valuation metrics for SRZNW: ROE of N/A (sector avg: 15%), net margin of -6,960.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SRZNW's AI grade for 2026?
Our dual AI analysis gives Surrozen, Inc./DE a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRZNW's free cash flow?
Surrozen, Inc./DE's operating cash flow is $-30.2M, with capital expenditures of $128.0K. FCF margin is -873.5%.
How does SRZNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,960.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 9.22 (avg: 2).